PDCD1 and metastatic malignant neoplasm: Blocking the programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) axis has improved the prognosis of numerous patients with advanced and metastatic cancer since its approval by the FDA in 2014 [2].